Anthony J. Gringeri
Institution Name:
Total Awards:
1
Award Value:
$5,391,016
Awards as PI
| Program Type | Institution | Grant Title | Award Value |
|---|---|---|---|
| Clinical Trial Stage Projects | ImmunoCellular Therapeutics | A Phase III randomized double-blind, controlled study of ICT 107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy | $5,391,016 |
| Total: $5,391,016.00 |
